Financial implications and logistical challenges associated with new dementia therapies Panel Discussion with Dr Alice Powell, Prof James Burrell, Ms Madelaine Rañola, RN - Primary Care Masterclass Podcast
General Practice Clinical Sessions Podcast · ArmchairMedical.tv/podcasts
Audio is streamed directly from the publisher (podcasts.captivate.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Panel Discussion Dr Alice Powell, Prof James Burrell, Ms Madelaine Rañola, RN
In this podcast, we delve into the financial implications and logistical challenges associated with new dementia therapies, particularly focusing on treatments such as dananimab and lacanemab. We discuss the estimated cost of these therapies, which can exceed $77,000 over an 18-month treatment period, and the potential out-of-pocket expenses associated with necessary scans and clinical assessments. The lecture emphasizes the high costs of both FDA-approved medications and the required diagnostic imaging, which could price many patients out of receiving these promising therapies. The discussion acknowledges the burden this cost poses on patients and the healthcare system, while also suggesting that the eventual acceptance of this treatment into public funding channels may depend on accumulating evidence of cost-effectiveness from early intervention.
The conversation shifts to the effectiveness of these therapies in improving patient outcomes, with participants debating whether these treatments can restore independent living for individuals with mild dementia. The consensus is that while these drugs may not fully restore cognitive function, they could potentially slow cognitive decline significantly in early-stage patients, leading to better long-term outcomes. The notion of societal perceptions of dementia contrasts sharply with approaches to cancer treatments, thereby reinforcing the need for more appropriate frameworks around funding and support for neurodegenerative diseases, including those with early-stage symptoms.
Addressing the complexities of voluntary assisted dying within the context of dementia care, we explore the legislative barriers that complicate access to these options for patients who may progressively lose decision-making capacity. The nuanced legal frameworks make it challenging for individuals with dementia to qualify for voluntary assisted dying, which raises ethical questions about autonomy and cognitive rights in progressive diseases.
Further segments cover the operational aspects of healthcare funding mechanisms, such as transitioning patients from the NDIS to aged care services upon reaching 65 years of age. Participants outline how existing funding structures will adjust to the new legislation, ensuring no patient should experience a loss of financial support due to age transitions. This segment highlights the legislative evolution aiming to establish a more structured resource allocation for individuals with neurodegenerative conditions.
The diagnosis and identification of conditions such as Creutzfeldt-Jakob Disease (CJD) are thoroughly examined, with a focus on advancements in diagnostic testing and the importance of consensus among specialists for accurate diagnosis. Further points in the discussion address the rarity of certain diseases in Australia, underscoring the need for a broad understanding of variances in symptomology and diagnostic measures unique to neurodegenerative disorders.
The role of dietary interventions and lifestyle choices in dementia prevention receives attention, with participants referencing studies supporting physical activity and social engagement as protective factors against dementia. Despite the popularity of alternative treatments, such as turmeric and curcumin, the emphasis remains on evidence-based practices shown to effectively modify dementia risk.
Lastly, we explore the relationship between cognitive reserve and dementia risk, emphasizing how educational background and occupational complexity correlate with resilience to cognitive decline. The challenges in identifying dementia in patients with high cognitive abilities are discussed, illustrating how some individuals may maintain function longer only to experience a rapid decline once symptoms emerge.
Throughout, the engagement emphasizes the necessity for a comprehensive, informed approach to dementia treatment—advocating for patients' rights while navigating the complexities of healthcare funding, legal frameworks, and evolving treatment paradigms. The session underscores the critical need for ongoing dialogue among healthcare professionals to enhance understanding and develop better care strategies for individuals with dementia and their families.
-------------------------------------------------------------------------------
Access thousands of premium conference podcasts and 'full video' podcasts including synchronised PowerPoint slides at https://www.armchairmedical.tv/podcasts
General Practitioners: Earn your full year's worth of CPD including Educational Activities, Reviewing Performance and Measuring Outcomes CPD Hours.
Discover more at https://www.armchairmedical.tv/podcasts
Press play. You’re at the conference.
In every episode of ArmchairMedical Conference Podcasts, we bring Australia’s leading medical conference education straight to your headphones.
No travel.
No full days away from clinic.
No disruption to your life.
Each episode features real conference lectures, captured live and carefully curated into short, practical, evidence-based podcasts designed for busy general practitioners.
Whether you’re commuting, exercising, or moving through the gaps of your day, this is conference-quality learning that fits real GP life.
If you value staying at the leading edge of medicine, but don’t have the time to attend every conference, this is the smart way to do it.
🎧 Press play. You’re at the conference.
About ArmchairMedical Conference Podcasts
ArmchairMedical Conference Podcasts transform Australia’s best medical conferences into on-demand audio education for GPs. Learn from leading clinicians and experts, anytime and anywhere, in a format designed to work with - not against - your day.
Enjoying the episode?
⭐ Rate this episode
➕ Follow the podcast
💬 Share it with a colleague who’d value conference learning without the time away
Disclaimer: Content is for health professionals and general educational purposes only. It is not medical advice or a substitute for independent clinical judgement. Always consult current guidelines, product information and local protocols. Views expressed are those of the presenters and not necessarily ArmchairMedical. ArmchairMedical accepts no responsibility or liability for any loss or harm resulting from reliance on the information provided.
Visit https://www.armchairmedical.tv/podcasts for more information.